



## Indian Pharmaceutical Alliance (IPA) to organise 6<sup>th</sup> India Pharmaceutical Forum (IPF) from 24<sup>th</sup> to 26<sup>th</sup> February 2021

- *The theme of 6<sup>th</sup> IPF 2021 is 'Patient Centricity: New Paradigm in Quality Management'*
- *Keynote address will be delivered by Ms. S Aparna, Secretary, Department of Pharmaceuticals*
- *An exclusive CEO Panel Discussion on 'The Impact of COVID-19 on Pharmaceutical Industry and the way forward'*
- *Indian and Global regulators along with industry experts will be deliberating on issues of pertinence*

**February 18, 2021:** The year 2021 will mark the 6th edition of the India Pharmaceutical Forum, an annual flagship event hosted by the Indian Pharmaceutical Alliance. The 6<sup>th</sup> IPF will be hosted virtually, entailing seamless accessibility, and is scheduled from 24th February to 26th February 2021. The theme of 6<sup>th</sup> IPF is ***Patient Centricity: New Paradigm in Quality Management***. It focuses on various aspects that define quality management in the pharmaceutical industry, in post-COVID era, reinstating Patient Centricity as its focus. The three-day conference will bring together dignitaries from the healthcare industry to express their views through discussions ensuing meaningful and actionable outcomes. IPF provides a knowledge sharing platform to subject matter experts for facilitating discussions resulting in meaningful and actionable outcomes.

The conference will commence with a Keynote address by **Ms. S Aparna, Secretary, Department of Pharmaceuticals**, and inauguration of IPA's Best Practices document. This will be followed by informative sessions on varied topics under quality management including **Inspection during COVID-19 and GDUFA III Negotiation** by *Mr. David Gaugh, Senior Vice President for Sciences and Regulatory Affairs, AAM*. An update on **USFDA Quality Standard Control** will be presented by *Mr. Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, USFDA*.

**Mr Sudarshan Jain, Secretary-General, Indian Pharmaceutical Alliance** said *"COVID-19 has once again reinforced the efforts of the healthcare industry towards a patient-centric approach. This year, the 6<sup>th</sup> Indian Pharmaceutical Forum will provide an engaging platform to facilitate a comprehensive discussion on the everchanging shift in quality management, led by significant voices of the industry. It will bring together relevant stakeholders from prominent organisations, leading pharma companies and regulatory bodies to discuss an action-oriented approach to operate in the future."*

*"IPA has always believed that patients across the world should be the centre of any discussion. We are dedicated to highlight and share best pharmaceutical practices while driving excellence in pharma quality."* Mr. Jain added.

**Mr. Satish Reddy, President, Indian Pharmaceutical Alliance** said *"The Indian pharmaceutical industry effectively rose to the challenges of COVID-19 and reinstated its potential in the global pharma landscape. Maintaining benchmark quality standards is pivotal for all Indian Pharmaceutical Alliance*



*(IPA) member companies. IPA is committed towards driving excellence in quality and safety standards and the 6th Indian Pharmaceutical Forum (IPF) is a step ahead to showcase collaborative approach of the industry towards quality management while addressing evolving patient needs.”*

The forum will also encompass five panel discussions on contemporary subjects such as **New Paradigm in Quality Management, Digitisation/Automation, and AI in operations** and more. **The last day will be concluded with a special panel discussion comprising CEOs of leading Indian Pharma companies** such as Cadila Healthcare, Cipla, Dr. Reddy’s, Lupin, Sun Pharma, and Torrent Pharma to deliberate on **‘The impact of COVID-19 on pharmaceutical industry’**.

Attached / Appended is the agenda for your reference.

For more information, please visit [www.ipa-india.org/events/forthcoming-events.aspx](http://www.ipa-india.org/events/forthcoming-events.aspx)

#### **About IPA**

Indian Pharmaceutical Alliance represents 24 research based national pharmaceutical companies. Collectively, IPA companies account for over 85 per cent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country’s exports of drugs and pharmaceuticals and service over 57 per cent of the domestic market. For more information, visit [ipa-india.org](http://ipa-india.org)

*For media queries, please contact:*

Ritika Dutt

+919820910855

[ritika@dyellowelephant.com](mailto:ritika@dyellowelephant.com)